Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, reviews the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for systemic mastocytosis. Dr Gerds emphasizes the need to consult the most up-to-date version of the guidelines when treating patients.
In this detailed webinar on systemic mastocytosis, Dr. Miti introduces Professor Prithviraj Bose, an expert in the field, who discusses the complexities of diagnosing and managing systemic mastocytosis…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
In an interview conducted at the 2025 European Society for Blood and Marrow Transplantation Annual Meeting, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
